Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects With Severe Asthma

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01006161

Enrollment

Registered

2009-11-02

Start date

2010-01-31

Completion date

2012-08-31

Last updated

2015-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

Given the strong inhibition of SCH 527123 on neutrophil migration to sites of inflammation, there is a theoretical reason for its use in patients with severe asthma where neutrophils are thought to play a significant role in the pathophysiology of the disease.

Interventions

DRUGSCH 527123

Low dose

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Subject must have severe asthma, be at least 18 to less than or equal to 70 years of age, of either sex, and any race.

Exclusion criteria

* Subject who has been diagnosed with COPD or any other clinically relevant lung disease, other than asthma (eg, cystic fibrosis, pulmonary fibrosis, bronchiectasis).

Design outcomes

Primary

Measure	Time frame
Severe asthma exacerbations, pulmonary function test data, and a change in symptoms	Measured over the duration of the trial.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026